Selecting one or more of the options below will update the content below.

Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    In-Person

    Levetiracetam for Persons at Risk for Alzheimer's Disease (ALEVIATE-2)

    What is this Study about?

    The goal of this study is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce abnormal brain signaling in the brain in individuals who are at an increased risk for developing Alzheimer's Disease. Only participants who show the abnormal brain signaling on a functional MRI (fMRI) scan of the brain will be enrolled in the study. Enrolled participants will receive 4 weeks of treatment with LEV and 4 weeks of treatment with placebo (a sugar pill). The study involves cognitive testing, genetic testing, bloodwork, ECGs, questionnaires and several brain imaging scans.

    Eligibility Criteria

    • Are between 55-85 years of age

    • Have a parent or sibling with Alzheimer’s disease or with dementia that may be due to Alzheimer’s disease (even if not diagnosed as such)

    • Feel your memory is getting worse

    • Get normal scores on tests of thinking and memory (will be done as part of the study)

    • Are able to undergo brain MRI scans

    • Have a study partner (friend or family member) willing to answer questionnaires about you

    • Show increased brain signaling during the screening fMRI scan (Note: We anticipate that most people who sign up for the study will NOT show the increased brain activity levels required to qualify for the study treatment)

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Comprendre la perception de la parole dans le bruit chez les personnes âgées.

    What is this Study about?

    Votre mémoire vous inquiète? Le laboratoire des neurosciences de la parole et de l'audition de l'Université Laval vous invite à participer à un projet de recherche visant à comprendre la relation entre la cognition, l'audition et ladifficulté de perception de la parole dans le bruit au cours du vieillissement. La participation implique un maximum de 3 visites au Centre de recherche CERVO. La compensation totale pour l’étude est de 150$. Un résumé écrit devotre fonctionnement cognitif vous sera remis à la fin de votre participation

    Eligibility Criteria

    Les critères de base pour participer sont :

    - Être âgé de 50 ans et +

    - Avoir le français québécois comme langue principale

    - Être droitier

    - Avoir des inquiétudes concernant le fonctionnement de sa mémoir

    Recruitment End Date

    Find Out More
  • Observational Study
    Online

    Nature-based Virtual Reality Intervention for Depression in Alzheimer’s Disease (VRN-AD)

    What is this Study about?

    This study looks at how an at-home nature-based virtual reality (VR) program may help people living with Alzheimer’s Disease manage behavioural and psychological symptoms of dementia (BPSD), such as depression. Caregivers and/or study partners will have the option of taking part in the study and providing feedback regarding the VR intervention. This project will explore how virtual reality can be used as a non-pharmacological approach to prolong aging in place for individuals with BPSD, as BPSD contributes to rates of institutionalization.

    Eligibility Criteria

    • Are 50 years or older
    • Have been diagnosed with mild to early-moderate Alzheimer's disease (including mixed dementia)
    • Are medically stable and able to take part safely
    • Experience mild to moderate depressive symptoms
    • Feel comfortable using basic technology, such as a tablet or headset
    • Have access to Wi-Fi and a smart device (such as a phone or tablet) for online sessions and study apps
    • Have someone available to be present during all study sessions

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer's Disease Psychosis

    What is this Study about?

    ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).

    The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

    Eligibility Criteria

    Male or female participants aged 55 to 90 years of age
    Must have a study partner
    Presence of psychotic symptoms for at least 2 months before Screening.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients With Cerebral Amyloid Angiopathy (CAA)

    What is this Study about?

    The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 50 months.

    Eligibility Criteria

    Male or female participants aged 50 years of age
    Has a history of previous clinical intracerebral hemorrhage.
    Has probable CAA.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

    What is this Study about?

    This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

    What is this Study about?

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Must have a study partner
    Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    What is this Study about?

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Eligibility Criteria

    Male or female participants aged 55 years of age to 90.
    Must have a study partner
    History of agitation due to AD.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension

    What is this Study about?

    The purpose of this study is to find out whether treatment with VHB937 is safe and beneficial in people with early Alzheimer's disease. The study will evaluate the safety of VHB937, as well as its effects on memory and other thinking abilities, on daily activities, and on changes in the brain. The study will also observe and measure how VHB937 is processed by the body and how the body responds to it.
    Official Title

    Eligibility Criteria

    Male or female participants aged 50 years of age to 85.
    Must have a study partner
    Diagnosis of Mild Cognitive Impairment (MCI) due to AD or mild AD

    Recruitment End Date

    Find Out More